Takeda Pharmaceutical Company Limited

Infinity Pharmaceuticals, Inc.

Globalfoundries Inc.

Nova Measuring Instruments Ltd.

Nova Corporation

Thar Pharmaceuticals, Inc.

Cenerx Biopharma, Inc.

Thar Pharma, LLC

Paul Isbester

Zhiyuan Zhang

Luckner Gerard Ulysse

Bruce Joseph Elder

Jeffrey Alan Stafford

Jun Feng

Pingda Ren

Stephen W Kaldor

Grant Jackson Palmer

Stephen L Gwaltney

Jonathon Stuart Salsbury

Michael Martin

Benjamin S Lane

Jason Kropp

Ning Shan

Mazen Hanna

David R Weyna

Miranda L Cheney

Xufeng Sun

Matthew J Sendelbach

Alok Vaid

Cornel Bozdog

Sripathy Venkatraman

Bingidimi Itute Mobele

Elisabeth C A Brot

Shay Yogev

Yoav Etzioni

Richard S Fornicola

Maxwell M Reeve

Taher E Kagalwala

Aron Cepler

Jonathan S Salsbury

Nigel Metcalfe

Brian P Haney

Daniel K Keefe, Jr

Philip B Kisanga

Paul R Brodfuahrer

ZhiYuan Zhang

Stephen L Ii Gwaltney

Polymorphs of chemical compounds that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including P13 kinase activity, are described herein. Also provided herein are processes for preparing compounds, polymorphs thereof, and pharmaceutical compositions thereof.

Formulations of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one

A process control method for manufacturing semiconductor devices, including determining a quality metric of a production semiconductor wafer by comparing production scatterometric spectra of a production structure of the production wafer with reference scatterometric spectra of a reference structure of reference semiconductor wafers, the production structure corresponding to the reference structure, the reference spectra linked by machine learning to a reference measurement value of the reference structure, determining a process control parameter value (PCPV) of a wafer processing step, the PCPV determined based on measurement of the production wafer and whose contribution to the PCPV is weighted with a first predefined weight based on the quality metric, and based on a measurement of a different wafer and whose contribution to the PCPV is weighted with a second predefined weight based on the quality metric, and controlling, with the PCPV, the processing step during fabrication.

Process control of semiconductor fabrication based on spectra quality metrics

Polymorphs of chemical compounds that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including Pl3 kinase activity, are described herein. Also provided herein are processes for preparing compounds, polymorphs thereof, and pharmaceutical compositions thereof.

Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one and methods of use thereof

A method and system are presented for use in controlling a multiple patterning process of n patterning stages subsequently applied to a sample to produce a target pattern thereon. The method comprises: providing intermediate measured data indicative of an optical response of the sample after being patterned by m-th patterning stage, 1&#x2264;m&#x3c;n; processing said intermediate measured data, determining at least a location parameter of a predetermined feature of the pattern, and generating measured data indicative of said at least one selected parameter; utilizing said at least location parameter of the predetermined feature for optimizing a data interpretation model for interpretation of measured data indicative of an optical response from the sample being patterned by k-th subsequent patterning stage, m&#x3c;k&#x2264;n.

Method for use in process control of manufacture of patterned sample

Preparation and characterization of novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl) phosphonic acid, suitable for pharmaceutical compositions in drug delivery systems for humans.

Crystalline forms

Polymorphs of chemical compounds that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein. Also provided herein are processes for preparing compounds, polymorphs thereof, and pharmaceutical compositions thereof.

Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1 (2H)-one and methods of use thereof

Processes for preparing isoquinolinones and solid forms of isoquinolinones

Compounds, pharmaceuticals, kits and methods are provided for use with DPP-IV and other S9 proteases that comprise a compound comprising: wherein M is N or CR; Qand Qare each independently selected from the group consisting of CO, SO, SO, and C&#x2550;NR; and each L, X, R, R, and Rare as defined herein.

Dipeptidyl peptidase inhibitors

Methods of making compounds of the formula (I) wherein the variables are as defined herein. Also, methods of making compounds that may be used to inhibit dipeptidyl peptidase. 

Growing community of inventors

Castleton, NY, United States of America

Paul Isbester